

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Sinco Pharmaceuticals Holdings Limited**

### **兴科蓉医药控股有限公司**

*(Incorporated under the laws of the Cayman Islands with limited liability)*

**(Stock Code: 6833)**

## **CHANGE OF JOINT COMPANY SECRETARY CHANGE OF AUTHORISED REPRESENTATIVE AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Sinco Pharmaceuticals Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that due to change of job assignment, Ms. Wong Yik Han (“**Ms. Wong**”) has resigned from and Mr. Li Kin Wai (“**Mr. Li**”) has been appointed to the following positions of the Company with effect from 31 March 2021:

- (i) Joint company secretary (the “**Joint Company Secretary**”); and
- (ii) Authorized representative pursuant to Rule 3.05 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

After the aforesaid changes, Ms. Peng Yunlu (“**Ms. Peng**”) will continue to serve as the other Joint Company Secretary.

Ms. Wong has confirmed that she has no disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of the Stock Exchange and/or the shareholders of the Company.

### **Biographical details of Ms. Peng**

Ms. Peng is currently the Deputy Director in the President Office of the Company. Ms. Peng is primarily responsible for coordinating the meetings of the Board and the shareholders, handling corporate disclosure pursuant to the Listing Rules as well as attending to corporate governance affairs. Ms. Peng joined the Group and has been working for Sichuan Sinco Pharmaceuticals Co., Ltd (“**Sichuan Sinco**”) since 2013. She has held important positions in Quality Management Department, Purchasing Department, Capital Department and Accounting Department in Sichuan Sinco during the period. Ms. Peng holds a master degree in International Business from University of Birmingham.

### **Biographical details of Mr. Li**

Mr. Li is a Manager of Corporate Services of Tricor Services Limited, an Asia’s leading business expansion specialist specializing in integrated Business, Corporate and Investor Services. Mr. Li has around 10 years of experience in the corporate secretarial field. Mr. Li is a Chartered Secretary and an Associate of both The Hong Kong Institute of Chartered Secretaries and The Chartered Governance Institute (formerly The Institute of Chartered Secretaries and Administrators). Mr. Li holds a master of Corporate Governance degree from The Open University of Hong Kong.

The Board wishes to take this opportunity to express its gratitude to Ms. Wong for her contribution during her tenure of offices and express its warmest welcome to Mr. Li for taking up the appointment.

### **WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES**

Reference is made to the announcement of the Company dated 22 January 2021 (the “**Announcement**”) regarding the waiver granted to the Company by the Stock Exchange from strict compliance with Rules 3.28 and 8.17 of the Listing Rules (the “**Original Waiver**”) for the period from 22 January 2021 to 24 October 2022 (the “**Original Waiver Period**”) on certain conditions. One of the conditions is that Ms. Peng would be assisted by Ms. Wong during the Original Waiver Period and the Original Waiver would be revoked immediately if and when Ms. Wong ceased to provide assistance to Ms. Peng. For further details of the Original Waiver, please refer to the Announcement.

In view of Ms. Wong's resignation and since Ms. Peng does not possess the qualifications of company secretary as required under Rule 3.28 of the Listing Rules, the Company has applied for, and the Stock Exchange has granted, a new waiver from strict compliance with Rules 3.28 and 8.17 of the Listing Rules (the "New Waiver") for a period from the date of said appointment of Mr. Li to 24 October 2022 (the "New Waiver Period") on the conditions that (i) Ms. Peng will be assisted by Mr. Li during the New Waiver Period and the New Waiver will be revoked immediately if there are material breaches of the Listing Rules by the Company; (ii) the Company shall notify the Stock Exchange at the end of the New Waiver Period for the Stock Exchange to re-visit the situation. The Stock Exchange expects that after the end of the New Waiver Period, the Company will be able to demonstrate that Ms. Peng can satisfy Rule 3.28 of the Listing Rules after having the benefit of Mr. Li's assistance such that a further waiver will not be necessary; and (iii) the Company will disclose details of the New Waiver, including the reasons for and the conditions of the New Waiver, by way of announcement.

### **REASONS AND GROUNDS FOR SEEKING THE NEW WAIVER**

Mr. Li, the newly appointed Joint Company Secretary, meets the requirements under Rule 3.28 of the Listing Rules. Mr. Li, as a Joint Company Secretary, will work closely with, and provide assistance to, Ms. Peng in discharging her duties as a Joint Company Secretary.

Although Ms. Peng does not possess the specified qualifications that are usually considered to be acceptable under Rule 3.28 of the Listing Rules, the Company considers that Ms. Peng, by virtue of her professional knowledge and experience in handling its corporate governance matters and with the support to be rendered by Mr. Li and his working team at Tricor Services Limited, would be capable of discharging her functions as a Joint Company Secretary.

The Company will ensure that Ms. Peng continues to have access to the relevant training and support in relation to the Listing Rules and the duties required of a company secretary of an issuer listed on the Stock Exchange. Ms. Peng and Mr. Li will take no less than 15 hours of professional training on any latest developments on the applicable Hong Kong laws and regulations in each financial year, in order to strengthen their experience and knowledge in respect of their duties and responsibilities under the Listing Rules.

Both Ms. Peng and Mr. Li will be advised by the Hong Kong legal adviser of the Company, as and when appropriate and required respectively.

By Order of the Board  
**Sinco Pharmaceuticals Holdings Limited**  
**Huang Xiangbin**  
*Chairman and Executive Director*

Sichuan, the PRC, 31 March 2021

*As at the date of this announcement, the executive director of the Company is Mr. Huang Xiangbin; and the independent non-executive directors of the Company are Mr. Lau Ying Kit, Mr. Wang Qing, Mr. Liu Wenfang and Mr. Bai Zhizhong.*